$23.39
Insights on Atricure Inc
Revenue is up for the last 2 quarters, 98.29M → 106.54M (in $), with an average increase of 7.8% per quarter
Netprofit is down for the last 3 quarters, -5.11M → -9.78M (in $), with an average decrease of 42.5% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 82.7%
In the last 3 years, Intuitive Surgical, Inc. has given 38.1% return, outperforming this stock by 103.6%
2.22%
Downside
Day's Volatility :3.38%
Upside
1.18%
4.15%
Downside
52 Weeks Volatility :62.39%
Upside
60.76%
Period | Atricure Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -28.94% | -0.7% | 0.0% |
6 Months | -34.63% | 6.6% | 0.0% |
1 Year | -43.72% | 3.7% | -1.5% |
3 Years | -66.31% | 14.0% | -21.8% |
Market Capitalization | 1.1B |
Book Value | $9.81 |
Earnings Per Share (EPS) | -0.66 |
PEG Ratio | -1.18 |
Wall Street Target Price | 56.14 |
Profit Margin | -7.62% |
Operating Margin TTM | -12.28% |
Return On Assets TTM | -3.24% |
Return On Equity TTM | -6.6% |
Revenue TTM | 399.2M |
Revenue Per Share TTM | 8.62 |
Quarterly Revenue Growth YOY | 21.0% |
Gross Profit TTM | 245.9M |
EBITDA | -16.3M |
Diluted Eps TTM | -0.66 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.74 |
EPS Estimate Next Year | -0.57 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 140.02%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 201.6M | ↑ 15.4% |
Net Income | -21.1M | ↓ 21.4% |
Net Profit Margin | -10.48% | ↑ 4.91% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 230.8M | ↑ 14.47% |
Net Income | -35.2M | ↑ 66.5% |
Net Profit Margin | -15.25% | ↓ 4.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 206.5M | ↓ 10.52% |
Net Income | -48.2M | ↑ 36.83% |
Net Profit Margin | -23.32% | ↓ 8.07% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 274.3M | ↑ 32.83% |
Net Income | 50.2M | ↓ 204.24% |
Net Profit Margin | 18.3% | ↑ 41.62% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 330.4M | ↑ 20.43% |
Net Income | -46.5M | ↓ 192.56% |
Net Profit Margin | -14.06% | ↓ 32.36% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 399.2M | ↑ 20.84% |
Net Income | -30.4M | ↓ 34.49% |
Net Profit Margin | -7.62% | ↑ 6.44% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 83.2M | ↓ 1.52% |
Net Income | -12.3M | ↓ 17.31% |
Net Profit Margin | -14.74% | ↑ 2.82% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 88.0M | ↑ 5.74% |
Net Income | -4.2M | ↓ 66.02% |
Net Profit Margin | -4.74% | ↑ 10.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 93.5M | ↑ 6.21% |
Net Income | -6.5M | ↑ 55.3% |
Net Profit Margin | -6.93% | ↓ 2.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 100.9M | ↑ 7.94% |
Net Income | -5.1M | ↓ 20.97% |
Net Profit Margin | -5.07% | ↑ 1.86% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 98.3M | ↓ 2.6% |
Net Income | -9.1M | ↑ 76.92% |
Net Profit Margin | -9.21% | ↓ 4.14% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 106.5M | ↑ 8.4% |
Net Income | -9.8M | ↑ 8.11% |
Net Profit Margin | -9.19% | ↑ 0.02% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 356.8M | ↑ 33.27% |
Total Liabilities | 107.4M | ↑ 0.79% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 557.9M | ↑ 56.37% |
Total Liabilities | 310.5M | ↑ 189.2% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 714.5M | ↑ 28.08% |
Total Liabilities | 302.1M | ↓ 2.7% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 615.3M | ↓ 13.89% |
Total Liabilities | 131.6M | ↓ 56.46% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 585.4M | ↓ 4.85% |
Total Liabilities | 128.7M | ↓ 2.18% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 613.9M | ↑ 4.87% |
Total Liabilities | 147.8M | ↑ 14.82% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 581.9M | ↓ 0.93% |
Total Liabilities | 131.6M | ↑ 0.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 585.4M | ↑ 0.61% |
Total Liabilities | 128.7M | ↓ 2.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 583.1M | ↓ 0.4% |
Total Liabilities | 128.3M | ↓ 0.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 594.2M | ↑ 1.9% |
Total Liabilities | 131.7M | ↑ 2.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 600.3M | ↑ 1.03% |
Total Liabilities | 137.4M | ↑ 4.32% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 613.9M | ↑ 2.28% |
Total Liabilities | 147.8M | ↑ 7.51% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.2M | ↓ 53.37% |
Investing Cash Flow | -85.4M | ↓ 2370.78% |
Financing Cash Flow | 100.2M | ↑ 3529.57% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.8M | ↑ 279.07% |
Investing Cash Flow | -2.1M | ↓ 97.49% |
Financing Cash Flow | 14.4M | ↓ 85.65% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.9M | ↑ 25.67% |
Investing Cash Flow | -156.2M | ↑ 7175.17% |
Financing Cash Flow | 189.4M | ↑ 1217.69% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.8M | ↓ 30.65% |
Investing Cash Flow | 23.5M | ↓ 115.05% |
Financing Cash Flow | -7.6M | ↓ 104.04% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.1M | ↑ 60.67% |
Investing Cash Flow | 44.0M | ↑ 87.23% |
Financing Cash Flow | -7.1M | ↓ 7.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.8M | ↓ 142.18% |
Investing Cash Flow | -3.2M | ↓ 115.78% |
Financing Cash Flow | -405.0K | ↓ 121.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 46.0K | ↓ 102.58% |
Investing Cash Flow | 7.0M | ↓ 316.18% |
Financing Cash Flow | 2.0M | ↓ 589.38% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↓ 8967.39% |
Investing Cash Flow | 28.8M | ↑ 311.5% |
Financing Cash Flow | -5.5M | ↓ 378.36% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0M | ↓ 173.82% |
Investing Cash Flow | -16.1M | ↓ 155.81% |
Financing Cash Flow | 3.0M | ↓ 154.27% |
Sell
Neutral
Buy
Atricure Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Atricure Inc | -26.58% | -34.63% | -43.72% | -66.31% | -13.6% |
Intuitive Surgical, Inc. | -4.7% | 35.81% | 38.95% | 38.38% | 112.57% |
Resmed Inc. | -8.97% | 22.05% | -22.01% | -15.48% | 75.2% |
Becton, Dickinson And Company | -2.32% | -10.48% | -8.43% | -10.33% | 1.9% |
West Pharmaceutical Services Inc | -4.64% | 0.62% | 4.23% | 19.12% | 238.38% |
Alcon Ag | -6.1% | 7.94% | 11.1% | 7.08% | 42.78% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Atricure Inc | 34.48 | NA | -1.18 | -0.74 | -0.07 | -0.03 | NA | 9.81 |
Intuitive Surgical, Inc. | 75.26 | 75.26 | 7.13 | 6.25 | 0.15 | 0.08 | NA | 37.77 |
Resmed Inc. | 30.61 | 30.61 | 1.75 | 7.41 | 0.22 | 0.11 | 0.01 | 30.47 |
Becton, Dickinson And Company | 52.86 | 52.86 | 1.34 | 12.95 | 0.05 | 0.03 | 0.02 | 87.68 |
West Pharmaceutical Services Inc | 48.1 | 48.1 | 6.72 | 7.62 | 0.21 | 0.12 | 0.0 | 39.2 |
Alcon Ag | 40.62 | 40.62 | 4.59 | 3.06 | 0.05 | 0.02 | 0.0 | 41.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Atricure Inc | Buy | $1.1B | -13.6% | 34.48 | -7.62% |
Intuitive Surgical, Inc. | Buy | $134.2B | 112.57% | 75.26 | 25.24% |
Resmed Inc. | Buy | $27.2B | 75.2% | 30.61 | 19.77% |
Becton, Dickinson And Company | Buy | $67.8B | 1.9% | 52.86 | 6.44% |
West Pharmaceutical Services Inc | Buy | $27.8B | 238.38% | 48.1 | 20.12% |
Alcon Ag | Buy | $39.5B | 42.78% | 40.62 | 10.3% |
Vanguard Group Inc
BlackRock Inc
AllianceBernstein L.P.
Champlain Investment Partners, LLC
Macquarie Group Ltd
First Light Asset Management, LLC
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
Organization | Atricure Inc |
Employees | 1200 |
CEO | Mr. Michael H. Carrel |
Industry | Health Technology |